FRATTAROLI JOSEPH 4
4 · Inhibikase Therapeutics, Inc. · Filed Dec 29, 2020
Insider Transaction Report
Form 4
FRATTAROLI JOSEPH
Chief Financial Officer
Transactions
- Conversion
Common Stock
2020-12-28$10.00/sh+44,143$441,430→ 44,143 total(indirect: By Flagship Consulting, Inc.) - Award
Stock Option (right to buy)
2020-12-22+100,000→ 100,000 totalExercise: $10.00Exp: 2030-12-22→ Common Stock (100,000 underlying) - Conversion
Convertible Note
2020-12-28→ 0 total(indirect: By Flagship Consulting, Inc.)Exercise: $10.00From: 2020-12-28Exp: 2021-12-31→ Common Stock (44,143 underlying)
Footnotes (1)
- [F1]One-third of the option will vest and become exercisable on 12/22/2021, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of the month beginning January 1, 2022.